TTRX Turn Therapeutics Inc.
$10.42▼ -1.79%
Healthcare
Other
Volume 98.4K
Avg Volume (10D) 82.2K
Key Metrics & Fundamentals
Market Cap
$316.43M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.57 - 16.45
% vs 50 MA
-10.68%
% vs 200 MA
50.81%
RSI-14
42.3
MACD Histogram
-0.1300
Beta (1Y vs SPY)
1.26
Free Cash Flow
-$929,162
Gross Rev
$0
Gross Profit
$0
EBITDA
$1.73M
COGS
–
Operating Exp
$1.63M
Operating Income
-$1.63M
EBIT
-$1.63M
Pretax Income
-$5.85M
Net Income
-$5.85M
EPS (Diluted)
-0.20
Price & Volume History
Loading chart…
Recent News
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
Business Wire · Oct 21, 2026 4:01 PM ET
A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech…
Pharma Voice · Oct 21, 2026 9:00 AM ET
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Business Wire · Sep 10, 2026 8:00 AM ET
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
Business Wire · Sep 9, 2026 8:00 AM ET
NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director
GlobeNewswire · Sep 8, 2026 7:00 AM ET
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
Business Wire · Aug 20, 2026 8:00 AM ET
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
Business Wire · Aug 12, 2026 4:30 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See TTRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.